DAX24.490 +0,6%Est505.796 +0,8%MSCI World4.343 -0,1%Top 10 Crypto11,63 -0,5%Nas23.468 ±-0,0%Bitcoin75.356 +1,8%Euro1,1756 -0,1%Öl61,95 +0,3%Gold4.368 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Bayer BAY001 Deutsche Telekom 555750 Novo Nordisk A3EU6F Lufthansa 823212 BYD A0M4W9 RENK RENK73 Allianz 840400 Siemens Energy ENER6Y Infineon 623100 Tesla A1CX3T BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet letzten Handelstag 2025 freundlich -- Rheinmetall, RENK, HENSOLDT & TKMS im Blick: Putin wird Ukraine Terror vor -- TUI, Palantir, Meta im Fokus
Top News
Consorsbank-Depot zu teuer? Mit diesem Broker sparst Du dauerhaft Gebühren Consorsbank-Depot zu teuer? Mit diesem Broker sparst Du dauerhaft Gebühren
Tesla-Aktie: So schneidet der E-Autobauer in einer Nutzer-Umfrage in Sachen Verlässlichkeit ab Tesla-Aktie: So schneidet der E-Autobauer in einer Nutzer-Umfrage in Sachen Verlässlichkeit ab
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

IDEAYA Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
28,60 EUR -0,40 EUR -1,38 %
STU
34,31 USD -0,49 USD -1,41 %
BTT
IDEAYA Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,62 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PJPB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45166A1025

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIDYA

IDEAYA Biosciences Aktien News

DatumMeistgelesen
PR NewswireIDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
PR NewswireIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
PR NewswireIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
PR NewswireIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
PR NewswireIDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
PR NewswireIDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
PR NewswireIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
PR NewswireIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
PR NewswireIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
PR Newswire/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
PR NewswireIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
PR NewswireIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
PR NewswireIDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
PR NewswireIDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
PR NewswireIDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
PR NewswireIDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
PR NewswireIDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
PR NewswireIDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer
PR NewswireIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.